Maloney, David G.

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Sorror, M. L., Maris, M. B., Storb, R., Baron, F., Sandmaier, B. M., Maloney, D. G., & Storer, B. (2005) · Blood

Hematopoietic Stem Cell TransplantationInflammatory Biomarkers in Disease Prognosis

Cited by 2,969

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., et al. (2020) · The Lancet

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 2,430

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation

CAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Cited by 2,112

Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

Gust, J., Hay, K. A., Hanafi, L.-A., Li, D., Myerson, D., Gonzalez-Cuyar, L. F., Yeung, C., Liles, W. C., Wurfel, M., Lopez, J. A., et al. (2017) · Cancer Discovery

CAR-T cell therapy researchBarrier Structure and Function Studies

Cited by 1,400

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy

Hay, K. A., Hanafi, L.-A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M., López, J. A., Chen, J., Chung, D., Harju-Baker, S., et al. (2017) · Blood

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 1,156

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells

Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 1,016

Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning

Fukuda, T., Boeckh, M., Carter, R. A., Sandmaier, B. M., Maris, M. B., Maloney, D. G., Martin, P. J., Storb, R. F., & Marr, K. A. (2003) · Blood

Antifungal resistance and susceptibilityHematopoietic Stem Cell Transplantation

Cited by 465

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells

Hirayama, A. V., Gauthier, J., Hay, K. A., Voutsinas, J. M., Wu, Q., Gooley, T., Li, D., Cherian, S., Chen, X., Pender, B. S., et al. (2019) · Blood

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 355

Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity

Jacobson, C. A., Hunter, B. D., Redd, R., Rodig, S. J., Chen, P.-H., Wright, K., Lipschitz, M., Ritz, J., Kamihara, Y., Armand, P., et al. (2020) · Journal of Clinical Oncology

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 352

The B-cell tumor–associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor

Hudecek, M., Schmitt, T. M., Baskar, S., Lupo-Stanghellini, M. T., Nishida, T., Yamamoto, T. N., Bleakley, M., Turtle, C. J., Chang, W.-C., Greisman, H. A., et al. (2010) · Blood

CAR-T cell therapy researchChronic Lymphocytic Leukemia Research

Cited by 266

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

Gauthier, J., Bezerra, E. D., Hirayama, A. V., Fiorenza, S., Sheih, A., Chou, C. K., Kimble, E. L., Pender, B. S., Hawkins, R. M., Vakil, A., et al. (2021) · Blood

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 205

Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products

Cornetta, K., Duffy, L., Turtle, C. J., Jensen, M., Forman, S., Binder-Scholl, G., Fry, T., Chew, A., Maloney, D. G., & June, C. H. (2018) · Molecular Therapy

Virus-based gene therapy researchCAR-T cell therapy research

Cited by 98

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016

Shadman, M., Li, H., Rimsza, L., Leonard, J. P., Kaminski, M. S., Braziel, R. M., Spier, C. M., Gopal, A. K., Maloney, D. G., Cheson, B. D., et al. (2018) · Journal of Clinical Oncology

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 86